COVID/Influenza Combination Vaccine is under clinical development by Novavax and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II drugs for Seasonal Influenza have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how COVID/Influenza Combination Vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
COVID/Influenza Combination Vaccine overview
ICC vaccine is under development for the prevention of seasonal influenza virus infections and coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome virus 2 (SARS-CoV-2). It is a quadrivalent hemagglutinin nanoparticle influenza and SARS-CoV-2 rs nanoparticle combination vaccine, administered through intramuscular route along with a saponin-based Matrix-M1 adjuvant.
Novavax is a biotechnology company that discovers, develops and commercializes vaccines to prevent a wide range of infectious diseases. The company develops genetically-engineered vaccine candidates harnessing three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. Its pipeline products include NVX-CoV2373 for coronavirus, NanoFlu for seasonal influenza, ResVax for respiratory syncytial syndrome and vaccines indicated for the prevention of Ebola virus, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). It is also developing proprietary immune stimulating saponin-based adjuvants. The company operates research and manufacturing facilities in Gaithersburg, Maryland; Uppsala, Sweden; and Bohumil, Czech Republic. Novavax is headquartered in Gaithersburg, Maryland, the US.
For a complete picture of COVID/Influenza Combination Vaccine’s drug-specific PTSR and LoA scores, buy the report here.